Navigation Links
Hepatitis B virus reemerges with long-term nucleoside analog treatment
Date:4/27/2011

A recently published study revealed that virological breakthrough (VBT) is common in patients receiving nucleoside analogs (NUCs) for chronic hepatitis B. Nearly 40% of the VBTs found were not related to antiviral drug resistance. Details of this retrospective study are published in the May issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

VBT is the first manifestation of antiviral drug resistance during NUC therapy of chronic hepatitis B. NUC drugs approved for treatment of chronic hepatitis B include lamivudine (LAM), adefovir (ADV), entecavir (ETV), telbivudine (TBV), and tenofovir (TDF). While the medications suppress the virus with few side effects, they do not eradicate HBV and require long-term treatment to provide clinical benefit. With long-term NUC therapy, studies have shown an increasing risk of drug resistance particularly with monotherapy regimens.

In the current study, Anna Lok, M.D. and colleagues from the University of Michigan Health System examined the incidence of VBT and genotypic resistance (GR) in 148 patients with chronic hepatitis B who were treated with NUCs between January 2000 and July 2010. The mean age of study participants was 45 years and 73% were male. Researchers reviewed medical records and recorded patient demographics, hepatitis B virus (HBV) markers, liver panel, blood counts and liver histology.

Results showed that during a mean follow-up of 38 months, 39 (26%) patients had at least one VBT, and upon retesting, 15 (38%) of these patients did not have a VBT and 10 had no evidence of GR. Researchers reported the probability of VBT, confirmed VBT, and GR at five years was 46%, 30%, and 34%, respectively. "Our analysis showed an alarmingly high rate of VBT in clinical practice and the only factor significantly linked to VBT was failure to achieve undectectable HBV DNA," said Dr. Lok.

HBV DNA decreased in the ten patients who initially experienced a VBT, but who did not have confirmed VBT or GR, when the same drug regimen was maintained. Nine of these patients had undetectable HBV DNA at the most recent follow-up, a mean of 7 months after the initial VBT. These data suggest that nonadherence to medication may be a common cause of VBT. "Counseling patients with chronic hepatitis B on the importance of medication adherence, and confirming reemergence of the virus and genetic mutations that cause resistance, can help to avoid unnecessary changes to antiviral treatments," advised Dr. Lok.


'/>"/>

Contact: Dawn Peters
healthnews@wiley.com
781-388-8408
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. New screening system for hepatitis C
2. Groundbreaking research to find vaccine for hepatitis C
3. 1 in 5 At-Risk U.S. Babies Doesnt Get Hepatitis B Vaccine
4. Vaccination, Prevention Is Beating Back Hepatitis
5. Bipartisan Capitol Hill Media Event: Health Experts, Lawmakers to Urge Federal Government to Fix the Funding Failure for Chronic Viral Hepatitis
6. Hepatitis C treatment less effective in urban minority patients
7. Researchers identify potential new target for treating hepatitis C
8. Donor kidneys from Hepatitis C patients needlessly denied to patients with that infection
9. Henry Ford Hospital atudy: Hepatitis C infection doubles risk for kidney cancer
10. New Drug Shows Promise for Curing Hepatitis C
11. Hepatitis C Tied to Higher Kidney Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... As part of its ongoing series ... 2016. Each webinar features a dynamic expert and thoughtful presentation to give attendees ... and facilities. Both events are free to attend, but registration is required. ...
(Date:2/10/2016)... Tenn. (PRWEB) , ... February 10, 2016 , ... ... the American Academy of Emergency Medicine , an emergency medicine professional ... practice management services . , The American Academy of Emergency Medicine, or ...
(Date:2/10/2016)... ... 10, 2016 , ... The Wickman Agency in Garland, TX ... local community. Pledging to select a new beneficiary every 60 days, the agency ... goal is to bring community awareness to important local causes by forming campaigns ...
(Date:2/10/2016)... , ... February 10, 2016 , ... 10 Best ... There were three leading bottled water brand owners that topped the list as a ... connectivity and optimize conversion. The premier brand was Tibet 5100, a top notch water ...
(Date:2/10/2016)... ... ... Dr. Jessica Barron, of Barron Family Dental in Thornton, Colorado , is ... the North Metro Denver area. The new dental practice focuses on comfort where patients ... the most relaxing environment. , While some dental visits can create anxiety for patients, ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... -- QT Vascular Ltd., together with its subsidiaries (the ... subsidiaries, the "Group"), is pleased to provide an ... ("ÄngioScore") (now owned by Spectranetics Corporation (NASDAQ: ... States Court of Appeals for the ... district court order (the "DCO").   The DCO had ...
(Date:2/10/2016)... Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ... fourth quarter and full year ended December 31, 2015. ... was a transformational year for Vanda with the continued ... market approval of HETLIOZ for Non-24," said Mihael H. ... Fanapt to our U.S. product portfolio builds on this ...
(Date:2/10/2016)... , Feb. 10, 2016 CSI Specialty Group ... the launch of the Specialty Pharmacy Podcast. A free, ... aimed at providing real-world education, discussion and context amongst ... --> --> The Specialty Pharmacy ... of CSI Specialty Group Suzette DiMascio, CHE, CMCE, CPC, ...
Breaking Medicine Technology: